WEXFORD,
Pa., Feb. 6, 2025 /PRNewswire/ -- COEPTIS, Inc.
(Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering
technology company dedicated to advancing cutting-edge technologies
and artificial intelligence at the forefront of innovative
biotechnology therapeutic solutions, today announced the successful
closure of an additional $5.7 million
in its final Series A Preferred Offering, bringing the total
financing round to $10 million. This
significant achievement highlights investor confidence in Coeptis'
innovative therapeutic solutions and its strategic pivot towards
technology-driven growth.
The financing was led by CJC Investment Trust, an entity
controlled by board member Christopher
Calise, through an increase in their initial investment in
the round. Under the terms of the latest financing, the Series A
Preferred is convertible into shares of the Company's common stock
at a price of $8.00 per share,
subject to limitations. Additionally, investors received an
aggregate 15% equity interest in the Company's newly formed
subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc. This
announcement follows an initial closure of $4.3 million in June
2024.
"We're thrilled to announce the successful closure of our second
Series A Preferred financing," said Brian Cogley, CFO of
COEPTIS. "This funding is pivotal as we expand our operational
capabilities and enhance shareholder value through our new
Technology Division. The integration of AI-driven tools,
particularly from our recent acquisition of the NexGenAI Affiliates
Network platform, is vital in revolutionizing our approach to
marketing and operational efficiencies in the highly regulated
biopharmaceutical sector."
The proceeds from this financing will be utilized to strengthen
the Company's balance sheet, repay outstanding obligations, and
support general corporate purposes, alongside the $4.3 million already raised. Moreover, the
additional capital will accelerate Coeptis' ongoing
integration of advanced AI solutions and automation capabilities,
enhancing not only research processes but also the overall
operational framework of the Company.
"This additional financing enables Coeptis to not just
fortify its mission in cell therapy but also empowers us to drive
innovation in technology and AI," added Dave Mehalick, President and CEO of COEPTIS. "By
fostering a culture of responsible innovation, we aim to capitalize
on diverse growth opportunities, creating a self-sustaining
business model that establishes a strong foundation for long-term
success and profitability."
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis
Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP
Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical
and technology company focused on developing innovative cell
therapy platforms for cancer, autoimmune, and infectious diseases.
Coeptis aims to advance treatment paradigms and improve patient
outcomes through its cutting-edge research and development
efforts.
The Company's therapeutic portfolio is underscored by assets
licensed from Deverra Therapeutics, which include an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. COEPTIS is also
developing a universal, multi-antigen CAR technology licensed from
the University of Pittsburgh
(SNAP-CAR), alongside GEAR cell therapy and companion diagnostic
platforms in collaboration with VyGen-Bio and distinguished medical
researchers at the Karolinska
Institute.
Building on its core competencies, COEPTIS has recently
established a Technology Division, which focuses on enhancing
operational capabilities through advanced technologies. This
division features AI-powered marketing software and robotic process
automation tools acquired from NexGenAI Solutions Group, designed
to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA,
COEPTIS is dedicated to advancing its mission within the regulatory
framework set forth by the FDA, ensuring that all activities align
with the highest standards of compliance and patient care. For more
information on COEPTIS, visit https://coeptistx.com
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the inability to recognize the anticipated
benefits of the Deverra licensed assets, which may be affected by,
among other things, competition, the ability of the Company to grow
and manage growth economically and hire and retain key employees;
(3) the risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (4) costs related to ongoing asset
development including the Deverra licensed assets and pursuing the
contemplated asset development paths; (5) changes in applicable
laws or regulations; (6) the possibility that the Company may be
adversely affected by other economic, business, and/or competitive
factors; and (7) the impact of the global COVID-19 pandemic on any
of the foregoing risks and other risks and uncertainties identified
in the Company's filings with the Securities and Exchange
Commission (the "SEC"). The foregoing list of factors is not
exclusive. All forward-looking statements are subject to
significant uncertainties and risks including, but not limited, to
those risks contained or to be contained in reports and other
filings filed by the Company with the SEC. For these reasons, among
others, investors are cautioned not to place undue reliance upon
any forward-looking statements in this press release. Additional
factors are discussed in the Company's filings made or to be made
with the SEC, which are available for review at www.sec.gov. We
undertake no obligation to publicly revise these forward-looking
statements to reflect events or circumstances that arise after the
date hereof unless required by applicable laws, regulations, or
rules.
Contacts
IR@coeptistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-completes-10-million-series-a-preferred-financing-round-reinforcing-commitment-to-technological-innovation-and-ai-integration-302369957.html
SOURCE Coeptis Pharmaceuticals, Inc.
